VIDEO: Over two dozen vasculitis drugs in development

Editor's note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

We are very excited that we have multiple, multiple pipeline medications. There's at least 25 drugs in the development by companies and different university in the domain of vasculitis. The key target in these medication include tyrosine, protein kinase, JAK one, JAK two, tyrosine protein, phosphotase non receptor types substrate. There's also trials in CAR T as well, which is coming up in vasculitis as well. So there's so many coming up in vasculitis and we are very excited that there will be so many options for our patients. We were very excited upfront when we had rituximab, but things are getting much, much better in that's a great news for our patients.